

CardiologyRounds™

www.cardiologyrounds.org

AS PRESENTED IN THE ROUNDS OF THE CARDIOVASCULAR DIVISION
OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS

Diastolic and Systolic Heart Failure — Similarities and Differences – Part 2

By KANU CHATTERJEE, MB, FRCP, FCCP, FACC, MACP

Diastolic and systolic heart failure are the two clinical subsets of the syndrome of heart failure (HF). There are considerable similarities, as well as differences, between the two entities. Part 1, in the last issue of *Cardiology Rounds*, presented the definition and diagnosis, incidence and prevalence, and prognosis and natural history of diastolic and systolic HF. Part 1 also introduced a section describing the changes in ventricular function, hemodynamics, and remodeling. Part 2, in this issue of *Cardiology Rounds*, continues this discussion and also presents an overview of the therapeutic options available for heart failure.

Changes in ventricular function, hemodynamics, and remodeling

The principal functional derangement in primary diastolic heart failure (HF) is impaired relaxation and increased passive stiffness.¹ The diastolic pressure volume relation shifts upwards and to the left (Figure 1). As a result, there is a substantially greater increase in diastolic pressure for any increase in volume.^{2,3} Left ventricular (LV) diastolic and end-systolic volumes are usually smaller than those in normal controls. LV ejection fraction is normal or higher than normal and LV mass and mass/volume ratio is substantially increased in patients with diastolic HF.

Kitzman et al assessed LV volumes, mass, and ejection fraction by echocardiography in patients with systolic and diastolic HF and in normal controls, and the results confirm these morphologic and functional characteristics (Table 1). LV wall thickness is significantly increased and, as ventricular volume decreases,⁴ wall stress is reduced. Decreased wall stress is the mechanism for the normal or even increased ejection fraction in patients with diastolic HF. Ventricular shape usually remains unchanged and significant secondary mitral regurgitation is uncommon. Mechanical dyssynchrony is also uncommon, even in the presence of conduction disturbance.

Systemic hemodynamics may be similar in systolic and diastolic HF. In primary systolic HF, the principal functional derangement is reduced ejection fraction, which results in a reduction in stroke volume and cardiac output. Increased LV volume and, frequently, associated abnormal diastolic filling, results in increased LV diastolic pressure, a passive increase in left atrial and pulmonary venous pressure, and post-capillary pulmonary arterial hypertension. Post-capillary pulmonary hypertension may cause right ventricular failure and systemic venous hypertension and, often, secondary tricuspid regurgitation.

In primary diastolic HF, the principal functional derangement is decreased LV diastolic compliance, which is associated with increased LV diastolic pressure. This causes similar pulmonary and right heart hemodynamic changes as those observed in primary systolic HF. In primary diastolic HF, LV stroke volume and, therefore, cardiac output, may decline because of decreased end-diastolic volume (preload-dependent) and also, not infrequently, due to depressed myocardial contractile function, particularly in elderly patients.⁵ In both systolic and diastolic HF, chronic elevation of pulmonary venous pressure may be associated with increased pulmonary vascular resistance, probably due to pulmonary vasoconstriction.

In both systolic and diastolic HF, ventricular remodeling is an important pathophysiologic mechanism for initiation and progression of HF. The characteristics of the remodeling features, however, are different in the two types of heart failure – which has important therapeutic implications. Concentric hypertrophy is characteristic of diastolic HF, whereas eccentric hypertrophy is more frequent in



BRIGHAM AND
WOMEN'S HOSPITAL



HARVARD
MEDICAL SCHOOL
TEACHING AFFILIATE

Cardiovascular Division (Clinical)

Christine Albert, MD	Jane A. Leopold, MD
Michelle Albert, MD	Eldrin Lewis, MD
Elliott Antman, MD	James Liao, MD
Donald S. Baim, MD	Peter Libby, MD
Kenneth Baughman, MD	(Division Chief)
Joshua Beckman, MD	Leonard Lilly, MD
Charles M. Blatt, MD	Bernard Lown, MD
Eugene Braunwald, MD	William Maisel, MD
Christopher Cannon, MD	Laura Mauri, MD
Ming Hui Chen, MD	Thomas Michel, MD, PhD
Michael Chin, MD, PhD	David Morrow, MD
Mark Creager, MD	Karen Moulton, MD
Akshay Desai, MD	Gilbert Mudge, MD
Elazer Edelman, MD, PhD	Anju Nohria, MD
Andrew Eisenhauer, MD	Patrick O'Gara, MD
Laurence Epstein, MD	Marc A. Pfeffer, MD, PhD
James Fang, MD	(Editor)
Mark Feinberg, MD	Jorge Plutzky, MD
Daniel Forman, MD	Jeffrey Popma, MD
Peter Ganz, MD	Shmuel Ravid, MD
J. Michael Gaziano, MD	Frederic Resnic, MD
Thomas Gaziano, MD	Paul Ridker, MD
Marie Gerhard-Herman, MD	Thomas Rocco, MD
Robert Giugliano, MD	Campbell Rogers, MD
Michael Givertz, MD	Maria Rupnick, MD, PhD
Samuel Z. Goldhaber, MD	Marc Sabatine, MD
Thomas B. Graboys, MD	Arthur Sasahara, MD
Howard Hartley, MD	Christine Seidman, MD
Carolyn Ho, MD	Andrew Selwyn, MD
Mukesh Jain, MD	Daniel Simon, MD
John Jarcho, MD	Laurence Sloss, MD
Paula Johnson, MD	Piotr Sobieszczyk, MD
Scott Kinlay, MD	Regina Sohn, MD
Jamil Kirdar, MD	Scott Solomon, MD
James Kirshenbaum, MD	Lynne Stevenson, MD
Bruce Koplan, MD	William Stevenson, MD
Gideon Koren, MD	Peter Stone, MD
Richard Kuntz, MD	Michael Sweeney, MD
Raymond Kwong, MD	Stephen Wiviott, MD
Michael J. Landzberg, MD	Justina Wu, MD
Richard Lee, MD	


Brigham and Women's Hospital

Fax: (617) 732-5291 Website: www.heartdoc.org

The editorial content of *Cardiology Rounds* is determined solely by the Cardiovascular Division of Brigham and Women's Hospital. This publication is made possible by an educational grant.

Cardiology Rounds is approved by the Harvard Medical School Department of Continuing Education to offer continuing education credit

Figure 1: The diastolic pressure-volume relation in patients with overt diastolic HF shifts upwards and to the left¹



Published with permission from Zile MR, et al. *N Engl J Med* 2004; 350(19):1953-9.

systolic HF. Eccentric hypertrophy is associated with increased myocyte length/ width ratio and the sarcomeres are deposited in series, allowing the myocytes to lengthen.⁶ In concentric hypertrophy, myocyte width is increased more than the length and the sarcomeres are deposited in parallel, allowing the increase in wall thickness. In concentric hypertrophy, increased myocyte protein synthesis has been documented. It has been hypothesized that decreased degradation of myocyte protein is more likely to occur in eccentric hypertrophy.⁶

The changes in the extracellular matrix and the abnormalities of collagen synthesis and degradation occur in both types of HF (Table 2). However, the matrix architectural changes are likely to be different since, despite fibrosis, progressive LV dilatation occurs in systolic HF, and LV dilatation is uncommon in diastolic HF (Figure 2).⁷ The abnormalities of activation of the matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) have been identified in both types of HF. Over-expression of several isoforms of metalloproteinases in the myocardium of the experimental post-infarction animal models has been observed.⁸ Remodeling following myocardial infarction (MI) occurs both in the infarct zone and in the remote non-infarct zone. Extracellular collagen matrix degradation in the infarct zone is associated with infarct expansion and, in the non-infarct zone, with global LV dilatation. Increased MMPs/TIMPs ratio with increased MMPs or decreased TIMPs favors adverse remodeling.⁹ There is upregulation of myocardial MMPs associated

Table 1: Echocardiographic LV morphologic and functional characteristics in primary systolic and diastolic HF compared to controls¹

	Controls	Systolic HF	Diastolic HF
LVEDV mL	102 ± 12	192 ± 10*	87 ± 10
LVESV mL	46 ± 11	137 ± 9*	37 ± 9
LVEF %	54 ± 2	31 ± 2*	60 ± 2 ⁺
LV Mass gm	125 ± 12	232 ± 9*	160 ± 9 ⁺
LV mass/ volume	1.49 ± 0.17	1.22 ± 0.14	2.12 ± 0.14 ⁺⁺
NE pg/ml	169	287	306 P = .007
BNP pg/ml	3	28	56 P = .02

LVED = Left ventricular end-diastolic volume

LVESV = Left ventricular end-systolic volume

LVEF = Left ventricular ejection fraction

LV = Left ventricle

* = Systolic heart failure vs controls P < .001

+ = Diastolic heart failure vs controls P < .001

++ = Diastolic heart failure vs controls P < .002

± = Mean (SE)

NE = Norepinephrine

BNP = B-type natriuretic peptide

with decreased fibrillar collagen cross-link formation, not only following acute MI, but also in patients with chronic systolic HF with cardiomyopathic ventricles.¹⁰ In addition to upregulation of soluble MMPs, certain membrane type MMPs appear to be increased in the myocardium of patients with systolic HF. This may be associated with the loss of myocyte connection with the extracellular collagen matrix and impaired sarcomere shortening.⁹

Increased plasma levels of MMPs are associated with severe systolic HF and probably reflect progressive remodeling.¹⁰ Plasma levels of TIMPs are inversely related to systolic function and echocardiographic measures of LV hypertrophy.¹¹ Circulating levels of amino-terminal propeptide of Type III procollagen (PIIINP), which reflect myocardial remodeling, are elevated in patients with dilated cardiomyopathy.¹² The extracellular matrix glycoprotein levels, (eg, tenascin-C), may be elevated in patients with systolic HF.¹³ The extracellular matrix remodeling is promoted by neurohormonal activation and activation of proinflammatory cytokines.^{9,14}

Table 2: Diastolic and systolic HF remodeling: myocyte and matrix changes

	Systolic HF	Diastolic HF
Myocyte		
Hypertrophy	+	+
Apoptosis	+	+
Necrosis	+	+
Myocardial fibrosis	+	+
Calcium regulation	-	-
MMPs/TIMPs	+	-
Collagen crosslinks	-	+

+ = Increased


- = Decreased or Impaired

MMPs = Matrix metalloproteinases

TIMPs = Tissue inhibitors of metalloproteinases

Figure 2: In patients with systolic HF, the left ventricle is dilated, while in patients with diastolic HF, the left ventricular size remains normal⁷

Upper panels: (contrast ventriculography).
Lower panel: histopathology of the myocardium in systolic HF. In addition to myocyte hypertrophy, diffuse fibrosis is evident.



Published with permission from Redfield MM. *N Engl J Med* 2004; 350(19):1930-1.


The changes in the extracellular matrix in primary diastolic HF have not been as extensively studied. In response to pressure overload, myocardial concentric hypertrophy is associated with increased myocardial fibrosis and altered structure

and composition of the extracellular matrix. In untreated hypertensive patients, collagen synthesis is upregulated with a decrease in plasma MMPs levels.¹⁵ Acute changes in pressure overload are associated with dynamic changes in TIMPs and MMPs. With an acute increase in pressure overload, myocardial TIMP activity tends to increase and MMP activity decrease.¹⁶ Whether similar changes occur in primary diastolic HF remains unclear. With pressure overload, activation of the renin-angiotensin-aldosterone system appears to contribute to extracellular matrix remodeling.

The precise stimuli for ventricular remodeling in primary systolic and diastolic HF have not been clearly delineated. In systolic HF, particularly in post-infarction patients, the extent of myocardial injury and the degree of depression of LV systolic function appear to be the major determinants for the initiation and progression of remodeling. A relatively small extent of myocardial damage is not associated with progressive ventricular dilatation¹⁷ (Figure 3). In patients with recent MI, reduced ejection fraction, despite recanalization of the infarct-related artery, is associated with remodeling. However, in patients with preserved ejection fraction, LV remodeling is attenuated.¹⁸ It is also likely that, even in patients with non-ischemic dilated cardiomyopathy, the extent of myocardial systolic dysfunction is an important determinant of progressive ventricular remodeling.

In patients with primary diastolic HF, the stimuli for ventricular remodeling remain unclear. The present or past pressure overload (hypertension) is very likely to be an important contributing factor. LV dilatation and, therefore, mechanical

Figure 3: Ventricular remodeling is attenuated with treatment with angiotensin-converting enzyme inhibitors¹⁷



Published with permission from Pfeffer MA. *J Card Fail* 2002;8 (Suppl 6): S248-52.

stress-induced remodeling is uncommon in the absence of an incident of myocardial injury, such as an MI.¹⁹ Neurohormonal activation, such as activation of the renin-angiotensin-aldosterone and adrenergic systems have been known to be important contributing factors in remodeling in systolic HF.²⁰ However, the same neuroendocrine abnormalities also occur in patients with HF and preserved ejection fraction.⁴ It is possible, however, that although the same neuroendocrine stimuli are present in both types of HF, different responses in primary systolic and diastolic HF occur during remodeling.

Myocyte loss, either by ischemic necrosis or enhanced programmed cell death (apoptosis), occurs in both types of HF.²⁰ However, the precise mechanisms of myocyte loss and the magnitude of myocyte loss in patients with primary systolic or diastolic HF have not been studied.

Therapeutic options (Table 3)

There have been considerable advances in the treatment of systolic HF, but very little progress has been made in the management of diastolic HF. For the relief of congestive symptoms, diuretics remain the principal therapy in both systolic and diastolic HF. In patients with acutely decompensated systolic HF, symptom relief and improvement in hemodynamics can occur with intravenous sodium nitroprusside, nitroglycerine and exogenous B-type natriuretic peptide (nesiritide) infusion.²¹ The role of such therapies in acutely decompensated diastolic HF remains unclear.

Angiotensin-receptor blocking agents (ARBs) and angiotensin-converting enzyme (ACE) inhibitors can reverse remodeling.²² In patients with chronic systolic HF, it has long been established that long-term treatment with ACE inhibitors, ARBs, and their combinations, and adrenergic antagonists, can cause sustained relief of symptoms and improvement in the quality of life.²³⁻²⁸ In patients with severe systolic HF, aldosterone antagonists can also improve symptoms and quality of life.²⁹ These therapeutic agents also substantially decrease mortality of patients with systolic HF. Furthermore, even in patients with asymptomatic systolic dysfunction, these pharmacologic agents have been shown to decrease the risk of development of overt heart failure.³⁰⁻³³ These beneficial effects have been linked to attenuation of progressive ventricular remodeling. Nitric oxide enhancing agents, such as the combination of hydralazine and isosorbide dinitrate, have been reported to improve prognosis in Black patients with systolic HF, even when added to background treatment with angiotensin and adrenergic inhibition therapy.³⁴

In patients with primary diastolic HF, however, only ARBs have been reported to decrease morbidity and, probably, mortality.³⁵ Statin therapy has been reported to decrease mortality in patients with primary diastolic HF.^{34,36} The mechanism for this potential beneficial effect with statins in diastolic HF remains unclear. Preliminary studies have also reported lower mortality with statin therapy in patients with systolic HF.³⁷ Prospective con-

Table 3: Diastolic and systolic HF: Management strategies

Diuretics are needed to relieve congestive symptoms in both systolic and diastolic HF

Digitalis may be effective in selected patients in both systolic and diastolic HF

Reduction in heart rate is beneficial in both systolic and diastolic HF

Angiotensin converting enzyme inhibitor

Decrease mortality and morbidity in systolic HF
Unproven benefit in diastolic HF

Angiotensin receptor blocking agent

Decrease mortality and morbidity in systolic HF
Decrease primarily morbidity in diastolic HF

Beta-blocker therapy

Decreases mortality and morbidity in systolic HF
Unproven benefit in diastolic HF

Hydralazine-nitrate

Decreases mortality and morbidity in systolic HF
Unproven benefit in diastolic HF

Aldosterone antagonists

Decreases mortality and morbidity in symptomatic patients with systolic HF
Unproven benefit in diastolic HF

Exogenous B-type natriuretic peptide

Decreases morbidity in decompensated systolic HF
Unproven benefit in diastolic HF

Chronic resynchronization therapy and/or implantable defibrillator

Decreases mortality and morbidity in systolic HF
Unproven benefit in diastolic HF

Implantable circulatory assist devices

May improve short-term survival in selected patients with refractory systolic HF
Unproven benefit in diastolic HF

Cardiac transplantation

May be of benefit in both systolic and diastolic HF

trolled studies will be required to evaluate the impact of statin therapy in improving the prognosis of patients with either systolic or diastolic HF. The role of aldosterone antagonist therapy in the management of patients with primary diastolic HF also remains uncertain.

Non-pharmacologic interventions, such as chronic resynchronization therapy, with or without, implantable cardioverter defibrillator, have been reported to improve prognosis of patients with refractory systolic HF.³⁹ LV assist devices that produce reverse remodeling have been of benefit in patients with systolic HF and may cause reverse remodeling by increasing collagen cross-linking and myocardial stiffness.⁴⁰ However, such therapies have not been shown as yet to be of benefit in patients with primary diastolic HF. Cardiac transplantation, however, is likely to be effective in both systolic and diastolic HF. It is apparent, therefore, that further research is necessary to understand the pathophysiologic mechanisms of primary systolic and diastolic HF and, therefore, to make further progress in the management of both types of heart failure.

Conclusion

Considerable differences exist in the pathophysiology and primary functional derangements between primary diastolic and systolic heart failure. However, hemodynamic consequences and neurohormonal activation may be remarkably similar. Although neurohormonal modulation is extremely effective therapy in systolic heart failure, such therapies, with the exception of angiotensin receptor blocking agents, have not been shown to improve morbidity-mortality in primary diastolic heart failure. Research must continue to further improve the prognosis of patients with heart failure, whether systolic or diastolic.

Acknowledgement: The author is grateful to Marci Yellin for her invaluable assistance in preparing the manuscript.

References

1. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004;350(19):1953-9
2. Aurigemma GP, Gaasch WH. Clinical practice: Diastolic heart failure. *N Engl J Med* 2004;351(11):1097-2105.
3. Grossman W: Defining diastolic dysfunction. *Circulation* 2000; 101:2020-1.
4. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. *JAMA* 2002;288(17):2144-50.
5. Aurigemma GP, Gaasch WH, McLaughlin M, et al. Reduced left ventricular systolic pump performance and depressed myocardial contractile function in patients >65 years of age with normal ejection fraction and a high relative wall thickness. *Am J Cardiol* 1995;76(10):702-5.
6. Carabello BA. Concentric versus eccentric remodeling. *J Card Fail* 2002;8 (Suppl 6):S258-63.
7. Redfield MM. Understanding “diastolic” heart failure. *N Engl J Med* 2004; 350(19):1930-1.
8. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? *Circ Res* 2001;89(3):201-10.
9. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? *Circulation* 2003; 108(11):1395-403.
10. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. *Circ Res* 2002;90(5):520-30.
11. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. *Eur Heart J* 2004;25(17):1509-16.
12. Rossi A, Ciccoira M, Golia G, et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. *Heart* 2004;90(6): 650-4.
13. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. *Am J Cardiol* 2004;94(11):1468-70.
14. Banfi C, Cavalca V, Veglia F, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. *Eur Heart J* 2005;26(5):481-8.
15. Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. *Int J Cardiol* 2000;75(1):43-7.
16. Deschamps AM, Apple KA, Leonardi, AH, et al. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. *Circ Res* 2005;96(10):1110-8.
17. Pfeffer MA. Janice M. Pfeffer Memorial Lecture. *J Card Fail* 2002;8 (Suppl 6):S248-52.
18. Bolognese I, Neskovic AN, Parodi G, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. *Circulation* 2002;106(18):2351-7.
19. Drazner MH. The transition from hypertrophy to failure: how certain are we? *Circulation* 2005;112(7):936-8.
20. De Marco T, Chatterjee K, Rouleau J-L, Parnley WW. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. *Am Heart J* 1988;115:809-15.
21. VMAC Investigators: Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. *JAMA* 2002;287:1531-40.
22. Solomon SD, Skali H, Nagesh S, et al. Changes in ventricular size and function in patients treated with valsartan, captopril or both after myocardial infarction. *Circulation* 2005;111:3411-9
23. Garg R, Yusuf S. For the collaborative group on ACE inhibitor trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA* 1995;273:1450-6.
24. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM overall programme. *Lancet* 2003; 362:759-66.
25. Granger CB, McMurray JV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: The CHARM alternative trial. *Lancet* 2003; 362:772-6.
26. McMurray JV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added Trial. *Lancet* 2003;362: 767-71.
27. Packer M, Fowler MB, Rocker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (Copernicus Study). *Circulation* 2002;106:2194-9.
28. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-CF). *Lancet* 1999;353:2001-7.
29. Pitt B, Zannand F, Remme WJ, et al. For the randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;341:709-17.
30. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med* 1992; 327:685-91.
31. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992;327(10):669-77.
32. Sharpe N, Murphy J, Smith H, Hanan S. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. *Eur Heart J* 1990;11 Suppl B:147-56.
33. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med* 1995;333(25):1670-6.
34. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. *N Engl J Med* 2004;351:2049-57.
35. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM Preserved Trial. *Lancet* 2003;362(9386): 777-81
36. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. A preliminary report. *Circulation* 2005;112:357-63.
37. Zile MR. Treating diastolic heart failure with statins: “phat” chance for pleiotropic benefits. *Circulation* 2005;112:300-3.
38. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. *Am J Cardiol* 2004;93:1124-9.

39. Abraham WT, Fisher WG, Smith AI, et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002;346:1845-53.
40. Klotz S, Foronjy RF, Dickstein ML, et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. *Circulation* 2005;112:364-74.



Kanu Chatterjee, M.B., FRCP, FACC, FCCP, MACP, is the Ernest Gallo Distinguished Professor of Medicine, Cardiology Division, University of California, San Francisco (UCSF). He graduated from the University of Calcutta, India, and received postgraduate training in England. He was elected as a Fellow to the Royal College of Physicians of Edinburgh, Scotland, and the Royal College of Physicians, London, in 1979. He is board certified in Internal Medicine (1973) and Cardiovascular Disease (1975). His research interests include ischemic heart disease, heart failure, and peripheral circulation. Dr. Chatterjee has authored or co-authored more than 300 publications and 95 book chapters, is the co-editor of the *Textbook of Cardiology*, and is a reviewer or served on the Editorial Boards of many journals, including the *New England Journal of Medicine* and the *American Journal of Cardiology*. He is currently an Associate Editor of the *Journal of the Heart Failure Society of America*. Dr Chatterjee received the Teaching Award, UCSF, Classes of 1989, 1990, 1994, 1991, and 1995; the first Floyd C. Rector Award for Excellence in Teaching, in 1995-1996; and the Academic Senate Distinction in Teaching Award for 2003-2004, both from the UCSF. He also received the prestigious "Gifted Teacher Award" of the American College of Cardiology in 1990. He has been a Visiting Professor at Mount Sinai Medical Center in New York, Stanford Medical Center, Cleveland Clinic, and Mayo Clinic. In 1993, Dr. Chatterjee received the first Melvin D. Marcus Memorial Award in recognition of his distinguished contribution as a "Gifted Teacher in Cardiology." He was inducted into the Gold-Headed Cane Society in 1998. In 1999, the Chatterjee Center for Cardiac Research was established by the Division of Cardiology, UCSF. Amongst his many awards, Dr. Chatterjee has also received the Holly Smith Award for Exceptional Service to the School of Medicine at UCSF in 2004 and, in 2005, the Distinguished Fellowship Award from the International Academy of Cardiology.

Dr. Chatterjee discloses that he has received speaker honoraria from Scios Inc., CV Therapeutics, Merck Sharp & Dohme, Pfizer, and Bristol-Myers Squibb.

A Trial for Heart Failure Patients with Preserved Systolic Function

TOPCAT (Treatment Of Preserved Cardiac function heart failure with an Aldosterone antagonist) is a multi-center, international, randomized, double-blind, placebo-controlled trial of the aldosterone antagonist, spironolactone, in 4500 adults with heart failure and left ventricular ejection fraction of at least 45%, recruited internationally from over 250 clinical centers.

The trial is sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health. New England Research Institutes, Inc. (NERI) and The Brigham & Women's Hospital (BWH) serves as the Clinical Trial Coordinating Center (CTCC).

For more information, please contact:

Website : <http://www.topcatstudy.com/>
www.topcatstudy.com
 Email : TOPCAT@neriscience.com
 Fax : (617) 673-9514



Harvard Medical School
 Department of Continuing Medical Education
 and
 Brigham and Women's Hospital
 Cardiovascular Division
 present



Proactive Venous Thromboembolism Prophylaxis

Saturday, February 4, 2006

Please join us for a 1-day symposium at Brigham and Women's Hospital. This program is a comprehensive and multidisciplinary overview of current thromboembolism prevention methods geared to physicians, nurses, physician's assistants, pharmacists, hospitalists, and hospital administrators. The curriculum will combine a review of established principals with state-of-the-art changes and novel concepts in thrombosis prevention.

For more information, please contact:

Kim Mahoney
 BWH Cardiovascular Division
 Tel. 617-732-7566
 email: kmahoney6@partners.org

Brigham and Women's Hospital,
 Cardiovascular Division website:
www.heartdoc.org

This publication is made possible by an educational grant from

Novartis Pharmaceuticals Corporation

© 2005 Brigham and Women's Hospital, Boston, Massachusetts, which is solely responsible for the contents. The opinions expressed in this publication do not necessarily reflect those of the publisher or sponsor, but rather are those of the author based on the available scientific literature. Publisher: **SNELL Medical Communication Inc.** in cooperation with Brigham and Women's Hospital, Boston, Massachusetts. TM*Cardiology Rounds* is a Trade Mark of SNELL Medical Communication Inc. All rights reserved. The administration of any therapies discussed or referred to in *Cardiology Rounds* should always be consistent with the recognized prescribing information as required by the FDA. **Snell Medical Communication Inc.** is committed to the development of superior Continuing Medical Education.